- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
- Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
- Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
- Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
- Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
More ▼
Key statistics
On Thursday, Exelixis Inc (EXEL:NSQ) closed at 22.49, -7.60% below its 52-week high of 24.34, set on Jan 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.00 |
---|---|
High | 23.23 |
Low | 22.46 |
Bid | 20.95 |
Offer | 24.00 |
Previous close | 22.49 |
Average volume | 1.96m |
---|---|
Shares outstanding | 303.19m |
Free float | 296.10m |
P/E (TTM) | 34.75 |
Market cap | 6.82bn USD |
EPS (TTM) | 0.6472 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼